EMBioSys
A non-pharmacological intervention to improve patient outcomes for triple-negative breast cancer
- Stage Product In Development
- Industry Medical Devices and Equipment
- Location North Andover, MA, USA
- Currency USD
- Founded August 2022
- Employees 2
- Incorporation Type C-corp
- Website embiosys.com
Company Summary
EMBioSys addresses a critical unmet need in the patient journey for triple-negative breast cancer providing a safe, non-pharmacological home-use therapy that is easy to deploy and enhances the standard of care.
The technology is novel, patented, simple to manufacture, and represents a very large market opportunity.
The scientific path has been paved by significant research and publications.
Team
-
Chief Executive Officer
Results driven executive with 35 years of product development and commercialization experience in the medical device industry. Proven leadership skills with a solid track record in both early start-up and established company environments. Experienced in a broad range of medical device technologies including iEF Therapy for treatment of solid metastatic cancers, cardiac assist & ablation devices, therapeutic ultrasound, all tissue dental lasers.
-
Co-Founder and Chief Scientific OfficerVish Subramaniam, PhD, is the inventor of EMBioSys' iEF Therapy. Dr. Subramaniam is Academy Professor of the Emeritus Academy at The Ohio State University (OSU), and Emeritus Professor in Mechanical and Aerospace Engineering (MAE) and the Chemical Physics Program. Dr. Subramaniam earned his B.S. and M.S. degrees from Columbia University in 1979 and 1981, respectively, and his PhD from Carnegie Mellon University in 1986.
Advisors
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.